Eaton Vance Management Genmab A/S Transaction History

Eaton Vance Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $51,036 - $65,432	-1,649 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $2,833 - $3,722	-79 Reduced 4.57%	1,649 $0
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $157,806 - $185,038	-3,798 Reduced 68.73%	1,728 $0
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $61,386 - $83,212	1,867 Added 51.02%	5,526 $226,000
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $113,136 - $162,459	3,659 New	3,659 $120,000

246

61.3M

159K

38K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.5B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.